Posted: 2 March 2026
MTPConnect has opened expressions of interest for a new funding round for medical devices under its Targeted Translation Research Accelerator (TTRA) initiative, with the opportunity having been supported by the Medical Research Future Fund.
The opportunity for non-dilutive funding has been made available to Australian small to medium enterprises (SMEs), including spin-outs and start-ups, working to accelerate promising medical devices to prevent, diagnose, treat and/or manage cardiovascular disease and the complications of diabetes (type 1 and type 2). Eligible medtech companies have been able to apply for up to $1 million in non-dilutive investment and have been required to provide a cash co-contribution, with applications closing on 30 March 2026 at 4:00pm AEDT.
“Access to funding remains the biggest challenge for startups and innovators, especially for medical devices, and MTPConnect is working to address that with this new funding round,” MTPConnect CEO Stuart Dignam has said.
“MTPConnect’s accelerator is highly sought-after by emerging life science companies, with the TTRA initiative already investing in 34 projects.
“Working with our in-house specialists and industry partners, companies are able to tap into the best local and international expertise to help them reach commercial proof-of-concept.
“We encourage medtech innovators working in cardiovascular disease and diabetes to take advantage of this new opportunity to secure non-dilutive funding and proven acceleration support,” he has said.
Funding Guidelines with details about eligibility and the application process have been made available on the MTPConnect website.
The opportunity has remained open for expressions of interest until 30 March 2026 at 4:00pm AEDT. An Information Session Webinar has been scheduled for 4 March 2026 at 1:00pm AEDT to provide further information.
